GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Degree of Operating Leverage

BRTX (BioRestorative Therapies) Degree of Operating Leverage : -0.06 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. BioRestorative Therapies's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -0.06. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for BioRestorative Therapies's Degree of Operating Leverage or its related term are showing as below:

BRTX's Degree of Operating Leverage is ranked better than
52.71% of 886 companies
in the Biotechnology industry
Industry Median: -0.02 vs BRTX: -0.06

BioRestorative Therapies Degree of Operating Leverage Historical Data

The historical data trend for BioRestorative Therapies's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Degree of Operating Leverage Chart

BioRestorative Therapies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -4.30 -0.18 -0.91 -0.14

BioRestorative Therapies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -0.84 -0.14 -0.14 -0.06

Competitive Comparison of BioRestorative Therapies's Degree of Operating Leverage

For the Biotechnology subindustry, BioRestorative Therapies's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Degree of Operating Leverage falls into.


;
;

BioRestorative Therapies Degree of Operating Leverage Calculation

BioRestorative Therapies's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -12.254 (Mar. 2025) / -13.468 (Mar. 2024) - 1 )/( 0.391 (Mar. 2025) / 0.15 (Mar. 2024) - 1 )
=-0.0901/1.6067
=-0.06***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


BioRestorative Therapies  (NAS:BRTX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


BioRestorative Therapies Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000